Statistics have indicated that at least one-third of New Zealander’s experience allergies and one in ten babies will develop an allergy-related issue. In Australia, one in three children are affected by eczema. Undoubtedly allergies have a significant impact upon an adult or child’s health and wellbeing.
Lactobacillus rhamnosus (LGG®) has been shown to provide protection from atopic eczema for the infant when administered to the mother before delivery and during breastfeeding. A randomised controlled trial was conducted in 159 mothers who had at least one first-degree relative or partner with atopic eczema, allergic rhinitis, or asthma. LGG® (20 billion CFU/daily) or placebo was given to expectant mothers in the last month prior to expected delivery and for six months postnatally, either to breastfeeding mothers or directly to the infants. The frequency of atopic eczema in the probiotic group was half that of the placebo group, 23% versus 46%, with the preventive effect not dependant on the mode of delivery.
The preventive effect of LGG® on atopic eczema also extends beyond infancy and is useful for anyone who exhibits these conditions.
DO YOU KNOW ANYONE THAT SUFFERS FROM ATOPIC ECZEMA, ASTHMA OR ALLERGIC RHINITIS?
PLEASE CONTACT ME FOR MORE INFORMATION. xo